Concepedia

Author

RS Cecchini

NRG Oncology

Also Known As

RS Cecchini

6

Publications

254

Citations

4

H-Index

26

Concepts

All Affiliations

NRG OncologyAllegheny Health NetworkUPMC Hillman Cancer CenterUniversity of Colorado Cancer CenterUniversity of Colorado Denver
RC

About

RS Cecchini is an author at NRG Oncology specializing in cancer therapeutics, breast cancer, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

4

4

251

2

Medicine

4

4

251

3

Pathology

2

2

108

4

Obstetrics

1

1

41

5

Pharmacology

1

1

41

RS Cecchini

×

4

Publications

251

Citations

4

H-Index

YearCitations

OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413.

TB Julian, J. P. Costantino, F.A. Vicini,

Cancer Research

2011

102

Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

F.A. Vicini, RS Cecchini, JR White,

Cancer Research

2019

58

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

L. Fehrenbacher, RS Cecchini, CE Geyer,

Cancer Research

2018

50

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

MF Rimawi, RS Cecchini, Priya Rastogi,

Cancer Research

2017

41

Page 1